Skip to main content
. 2019 Oct 24;14(10):e0223863. doi: 10.1371/journal.pone.0223863

Fig 1. KM survival curves.

Fig 1

A: Relapse-free survival rate B: Disease-progression-free survival rate progression C: T2-lesion-free survival rate D: Gd+-lesion-free survival rate E: NEDA-3 survival rate. The large confidence interval beyond 48 months observed in B, D and E in second-line treatment was due to algorithm artefact linked to low observation availability. Abbreviations: KM, Kaplan–Meier; INF, interferon beta; GA, glatiramer acetate; FTY, fingolimod; NAT, natalizumab; Gd+, gadolinium enhancement; NEDA-3, no evidence of disease activity.